相关临床试验
0
0 进行中
药物批准
722
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Collegium Pharmaceutical closed a $980 million syndicated credit facility in December 2025, replacing existing debt with lower-cost financing and providing additional capacity for business development. - The company issued 2026 guidance projecting $805-825 million in net product revenues and announced authorized generic supply agreements for Nucynta and Nucynta ER with Hikma Pharmaceuticals USA. - The new credit facility, priced at SOFR plus 2.75% initially, is expected to reduce annual interest costs while supporting future debt repayment and portfolio expansion efforts. - Despite improved financial flexibility, the company continues to face concentration risks from its pain and ADHD portfolio, regulatory scrutiny of opioids, and potential generic competition.
- Hikma Pharmaceuticals has launched TYZAVAN™, the first FDA-approved ready-to-use vancomycin injection with room-temperature stability, eliminating preparation time in critical sepsis cases. - The glycopeptide antibiotic is indicated for septicemia, infective endocarditis, skin infections, bone infections, and lower respiratory tract infections in adults and pediatric patients over one month old. - TYZAVAN™ offers seven different strengths (0.5g-2g) with 16-month shelf life at room temperature, designed to address the urgent need for rapid antibiotic administration in sepsis where survival rates decrease by 15% after 87-113 minutes. - The ready-to-use formulation streamlines hospital workflows by eliminating compounding, thawing, and assembly steps while reducing medication errors and handling risks for healthcare teams.
- The US Solicitor General urged the Supreme Court to hear Hikma Pharmaceuticals' appeal challenging a ruling that found the company induced patent infringement through its generic Vascepa labeling. - The government argued that Hikma shouldn't be penalized for using a "skinny label" that accurately described their product as the generic version of Amarin's heart medication. - The case centers on Vascepa, a heart medicine approved in 2012 for treating excessive triglycerides and expanded in 2019 for additional cardiovascular indications. - The dispute highlights critical issues around generic drug labeling practices and patent protection in the pharmaceutical industry.
- Hikma Pharmaceuticals launched STARJEMZA (ustekinumab-hmny) on November 6, 2025, marking the company's first biosimilar entry into the US market. - The biosimilar references Janssen's STELARA and is approved for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. - STARJEMZA became the seventh ustekinumab biosimilar to receive FDA approval on May 22, 2025, developed by Bio-Thera under a 2021 partnership agreement. - The launch represents a significant milestone for Hikma's biosimilar strategy and adds another treatment option for patients with inflammatory conditions.
